LUNG CANCER RESEARCH
(CHARITY COMMISSION NO. 1101823)
ACCOUNTS
31 DECEMBER 2024

LUNG CANCER RESEARCH
(CHARITY COMMISSION NO. 1101823
ACCOUNTS FOR THE YEAR ENDED 31 DECEMBER 2024
CONTENTS
PAGE
Trustees, Report
Accountants, Report
Independent Examiners Report
Balance Sheet
Statement of Financial Activities
Notes to the Accounts
10

LUNG CANCER RESEARCH
(CHARITY COMMISSION NO. 1101823)
TRUSTEES. REPORT FOR THE YEAR ENDED 31 DECEMBER 2024
Registered Charity Number
1101823
Prlnclpal Address
cjo Kreston Reeves LLP, 168 shO￿dI1￿ HKJh Street, 2nd Floor.
London, E16RA
Governing Document
Sett]emenl t)eed dated 20th January 2004
How Constitulod
As a trust
Objects of the Charlty
The assets a￿ held on Irusl to fund dinieAI laboratory and
epidemiological research into the causes. prevention and treatment
of Lung can￿r.
In setting our objecb.ves and planning our activlties the Trustees
have given careful consideration to the Charity Commission's
general guidance on publi¢ be￿frt.
Accountants
Kreston Reeves LLP
2nd Floor, 168 Shoreditch HvJh Street
London
E1 6RA
Bankers
HSBC Bank PIC
12 Hampstead H￿h Street
Hampslead
London
NW3 1PY
Trustses
Robin Ellison {retired 17th February 2025)
Alastair Meeks
Michael Seckl
Nim Wybom
Trust•• Sèlècllon
Appointrnent by existing trustees
MISSION STATEMENT
Introductlon
Lung Can￿r Research was established as a registered charity in 2004 to support the research in Ihe field
of lung cancer.
Lung cancer 1$ poody supported by the mainstream cancer charities. partly because it is seen a8 a 8elf-
inflicted disease in many cases.
There are four truste85 of the charity..
Robin Ellison (retired 171h FebNary 2025)
Mr Ala$tsir Meeks
Professor Michael Sed(I
Ms Nicci Wybom
Professor Ellison and Alastair Meeks are eXperien￿d trust lavryers. Professor Seckl is a wofld-leading
researcher in the field of lung Can￿r. Ms Wybom is a lung cancer survivor.

LUNG CANCER RESEARCH
ICHARITY COMMISSION NO. 11018231
TRUSTEES. REPORT FOR THE YEAR ENDED 31 DECEMBER 2024
Ala$tslr Meeks
Alastair Meeks is a retired soliutor. Until May 2020 he was a partner in Pin8ent Masons and practised
pensions law.
He was chair of the Association of Pension Lawyers from 2CM)7 to 2009 and is a Fellow of the Pensions
Management Institut8.
He acted in relation to many landmark ￿nsiOn cases, induding the ITN case and BESTrustees v Stuart,
both of which explored the interaction befv￿n explanatory literature and trust documentation. He acted
for the trustees of Anglo United Pension Scheme arKI the Dexion Scheme, and in the prockss helped
prompt the eslablishment of the DWP'S Financial Assistance Scheme.
He is the author of Tolley's Pensions Cases. the definttNe V￿rt< on the subied and currently edits the
pensions cases section of Tollels Pensions Law.
He is now taking up a rts￿ as a professional trustee wrth Zedra as from October 2023.
Profo$$or Se¢kl
Michael Seckl, MD, PID, Fmedsa trained medicine and suence al University College London (United
Kingdom} obtaining a Bsc in immunology in 1983 and his MBBS in 1986. He did his general professional
and specialist medical oncology training on the London carcuit, and became a femow of the Royal College
of Physicians. He obtained his PhD in biochemistry in 1995 from the London Research Institute {nt)W
known as the CRICKIIUniversity College London and was that year appointed as a senior
18clurerlhonorary consuftant in medical oneology at Charing Cross Hosprtal in London. now part of Imperial
College London.
He then established his own rw8ear¢h groups y￿rkIng on cell signalling in lung can¢xr and trophobla$ti¢
cancers supported by grants from Cancer Research UK. the Medical Research Council. Wellcome TTUSt,
Wellbeing. industry. and others. He was promoted to reader in 2002 and professor of molecular oncology
in 2004, when he a150 took on the directorship of the Charing Cross Gestational Trophoblaslic Diseasè
Centre and Ihe SUpra￿910Thal Tumour Marker Assay serv1￿.
Professor Seckl also leads the Imperial College Experimental Can￿r Medicine Cenlre. the Imperial
Cancer Trials unil, runs the London Lung Cancer Alliance and has run multiple Phase 1-111 trials. He is on
the editorial board of several journals and chairslsits on several grants committees. He is the immediate
past-pre$ident of the Royal Society of Mèdicine Oncology section and European organisat￿n for the
Treatment of Trophoblaslic Oisease. He was also pasl president and is the current treasurer of the
International Society for the Study of Trophoblasti¢ Disease and holds an honorary professorship with th&
Peking Union Medical College in China.
He also established and now co-leads the gynaecological cancEr domain wrthin the European Rare Adult
Cancer Neknrk IEURACANI. Educationally, he was director of postgraduate studies for the Depathent
of Surgery and C8n¢er with overall responsibility for 200 MSdMRes and 400 PhD students between 2012-
2022.
Within his own research group, he and his leam have T￿l¥ed numerous national and inlernational
awards and in the past 5 years have raised over £18M of grant income. He has published over 280 peer
reviewed manuscripts many appearing in leading scientffic and medical joumals such as Lancet. Lancet
Oncolo9y, New England J of Medicine. Nature communications. Science Translational Mediane and J
Clinical Oncology. In ￿CognItion for his conlTibutions to medical s￿nCe and his intemational leadership he
was made a Fellow of the Academy of Medical Suences in 2017. He remains committed to teaching,
research. and his patienly.

LUNG CANCER RESEARCH
(CHARITY COMMISSION NO. 1101823)
TRUSTEES. REPORT FOR THE YEAR ENDED 31 DECEMBER 2024
Nicci Wyborn
Nicci is a Senior Pensions Consuttant in the Pinsent Masons Pensions Solutions buSI￿sS at Pinsenl
Masons. In her current role she specialises in risk, goveman¢e and project management setvices for
clients wrth both defined benefit IDBI and defined contr*)ution IDCI pension schemes, working closely with
trustee boards, Pensions Managers and HR D1￿CtorS. Clients indude a £5.5 billion pension scheme
IDBIDCI, a £1 billion pension s¢heme IDBlwth AVCS). a £700 million pension scheme (open DB) and
£300 million pension scheme {DBIDCI. Nicci had been at Pinsent Masons for neady 23 years starting her
Ca￿er 8$ a PA in the pensKJns group, before moving to Pinsent Masons Pensions Solutions in 2017. Ni￿1
had lung surgery in 2018 for a carcinoid lung tumour so the WO￿ funded by the charity is extremely
important to her.
I dedare that in my Capacity of charity Iwstee, that:
- Ihe Trustees have approved the report above" and
have authorised me t
sign it on their behalf.
AlaslaSr Meek5
Trustee

LUNG CANCER RESEARCH
(CHARlfl COMMISSION NO. 1101823)
ACCOUNTANTS. REPORT FOR THE YEAR ENDED 31 DECEMBER 2024
In accordance wtth the engagement letter of 3 September 2013 we have prepared the accounts, set out on
pages 8 to 10, from the accounting records of the Trust&s and information and explanations given to us.
These accounts have been compiled in accordance wrth the accounting policies set out in Note 1 to these
accounts. These accounts are not intended to comply fully with the provisions of'UK Generally Accepted
Accounting Principles,.
This report is made to the Trustees of Lung Cancer Research Trust, in accordance wFth the tems of our
engagement. Our work has been undertaken so that we might prepare the accounts, report that we have done
so and state those matters which we feel should be drawn to the Twstees, attention and for no other PUTPOBe.
To the fLJllest extent pemiitted by law, we do not accept or assume responsibility to anyone, other than the
Trustees. for our work or for this report.
We have carried OLrt this engagement in accordance with technical guidelines issued by the Institute of
Chartered Accountants in England & Wales and by the Society of Trust and Estate Practitioners. We have
compiled this report with ethical guidance laid down by those bodies.
We have not been instructed to carry out an audit of these accounts. For this reason, we have not verified the
accuracy or completeness of the accounting records or information and explanations given to us and we do not,
therefore, express any opinion on Ihese accounts.
Il,,k Lgs LL
Kreston Reeves LLP
Chartered Accountants
2nd Floor
168 Shoreditch High Street
London
E16RA
ACCOUNTS APPROVAL CERTIFICATE
We approve these accounts and confimi that we have made available all relevant records and
information for their preparation.
Robin Ellison
Alastair Meek
y A￿TR￿s
Michael Seckl
Nicci Wybom

LUNG CANCER RESEARCH
(CHARI￿ COMMISSION NO. 1101823)
INDEPENDENT EXAMINER'S REPORT FOR THE YEAR ENDED 31 DECEMBER 2024
I report on the accounts for the year ended 31 st December 2024 which are set out on pages 8 to 10.
Res
ective Res
onsibilities of Trustees and Examiner
The charity's trustees are responsible for the preparation of the accounts. The charity's trustees consider that an audit is
not required for this year under section 144 of the Charities Act 2011 {"the Charities Act") and that an independent
examination is needed.
It is my responsibility to=
examine the accounts under section 145 of the Charities Act,
lo follow the procedures laid down in the general Directions given by the Charity Commission
{under section 145{5}{bl of the Charities Act. and
to state whether particular matters have come to my attention.
Basls of Examlnerfs Re
ort
My examination was carried out in accordance with general Directions given by the Charity Commission. An examination
includes a review of the accounting records kept by the charity and a comparison of the accounts presented wilh those
records. It also includes consideration of any unusual items or disclosures in the accounts, and seeking explanations
from the trustees conceming any such matters. The procedures undertaken do not provide all the evidence that would
be required in an audit, and consequently no opinion is given as to whether the accounts present a 'true and fair, view
and the report is limited lo those matters set out in the statement below.
Inde
endent Examlnerfs Re
ort
In connection with my examination, no matter has come to my attention:.
Which gives me reasonable cause to believe that in any material respect the requirements
- to keep accounting records in accordance with Section 130 of the Chanties Act., and
- to prepare accounts which accord with the accounting records and to comply with the
accounting requirements of the Charities Act
have not been met., or
to which, in my opinion, attention should be drawn in order to enable a proper understanding
of the accounts to be reached.
26.01.2026
Jerry Canny FCCA, CPA
Canny & Associates
Chartered Certlfled Accountants
60 Cannon Street
London
EC4N 6NP
Date

LUNG CANCER RESEARCH
(CHARITY COMMISSION NO. 1101823)
BALANCE SHEET AS AT 31 DECEMBER 2024
UNRESTRICTED
FUNDS
UNRESTRICTED
FUNDS
31 December 2024
31 December 2023
Current assets
HSBC Bank PIC
340.966
370,100
Total cash funds
370,100
Creditors within one year
Accountancy charges
Independent Examination charges
4.200
900
4,080
Net agsets
335.8
366,020
Funds of the Charity
Cash funds brought fopward, 31 December 2023
Net receipt?Ilpayments) during the year
366,020
(30,154)
471,656
{10Jf,638)
Total funds
335,866
366,020
Signed bytheTrusteeson.........................................................
Robin Ellison
Alastair Meek
Michael Seckl
Nicci Wyborn

LUNG CANCER RESEARCH
(CHARITY COMMISSION NO. 1101823)
STATEMENT OF FINANCIAL ACTIVITIES (SOFA) FOR THE YEAR ENDED 31 DECEMBER 2024
UNRESTRICTED
FUNDS
UNRESTRICTED
FUNDS
31 December 2024
31 December 2023
Note
Incoming resources
Donations received
67,744
9,071
Total incoming resources
Resources expended
Accountancy charges
Independent Examination charges
Bank charges
Imperial College for funding for lung cancer research
Administration Expenses
Registration with the Fundraising Regulator
2,100
900
116
94.496
286
2,100
133
111,507
917
50
Total resources expended
Net movement In funds
(30,154)
{105,636)
Total funds brought forward, 31 December 2023
366,020
471,656
Total funds as at 31 D•c•mb•r 2024
66,020

LUNG CANCER RESEARCH
(CHARITY COMMISSION NO. 1101823)
NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31 DECEMBER 2024
Accounting policies
Provision is included for all known current liabilities. Contingent and future liabilities are not included,
except where mentioned below by narrative note.
Assets are shown at their value at the balance sheet date.
Income Tax (In. Capital Gains Tax (CGT) and Inheritance Tax (IHT)
The trust, as a charity, is exempt from IT and CGT on its investment income and capital gains. None of
the restrictions on this relief, imposed by tax legislation, apply for this year.
The trust is also exempt from IHT while its funds continue to be held or applied for charitable purposes.
3 Donatlons
The Trustees received the following donations during this year'.-
2024
2023
Multiple payments
Charities Trust
Charitable Giving
Charities Aid Foundation
Paypal Giving Fund
Just Giving
Memory Giving
Other
745
80
275
603
120
110
4,216
4,022
24,592
221
3,991
Single payments
Donatis
303
Legacies from estates
Christine Bellamy
37,537
87.744
9,07
10